AI integration in the development of drugs accelerates research, reduces costs, and improves accuracy, significantly benefiting the pharmaceutical business.
Integrating AI in drug discovery enhances efficiency, reduces waste, and boosts development, creating a cost-effective and sustainable way for new therapeutics.
Market growth in medical device contract manufacturing, driven by chronic illnesses and advanced tech, is set to reach $130 bn by 2030 from $65 bn in 2022.
Biopharma giants are gearing up for mergers as $183.5B in annual sales face patent expirations; J&J and Merck lead in dealmaking potential, says Morgan Stanley.
The European Pharmacopoeia confirmed in June 2024 the removal of the rabbit pyrogen test- RPT from its monographs, replacing it with in vitro alternatives.
